GB201311475D0 - Polypeptides - Google Patents
PolypeptidesInfo
- Publication number
- GB201311475D0 GB201311475D0 GBGB1311475.6A GB201311475A GB201311475D0 GB 201311475 D0 GB201311475 D0 GB 201311475D0 GB 201311475 A GB201311475 A GB 201311475A GB 201311475 D0 GB201311475 D0 GB 201311475D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1311475.6A GB201311475D0 (en) | 2013-06-27 | 2013-06-27 | Polypeptides |
| PCT/EP2014/063442 WO2014207063A1 (en) | 2013-06-27 | 2014-06-25 | Cd86 variants with improved affinity for ctla-4 |
| EP14732247.3A EP3013854B1 (en) | 2013-06-27 | 2014-06-25 | Cd86 variants with improved affinity for ctla-4 |
| JP2016522479A JP6621741B2 (ja) | 2013-06-27 | 2014-06-25 | Ｃｔｌａ−４に対する親和性が改善したｃｄ８６バリアント |
| US14/901,202 US9834589B2 (en) | 2013-06-27 | 2014-06-25 | CD86 variants with improved affinity for CTLA-4 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1311475.6A GB201311475D0 (en) | 2013-06-27 | 2013-06-27 | Polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201311475D0 true GB201311475D0 (en) | 2013-08-14 |
Family
ID=48999077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1311475.6A Ceased GB201311475D0 (en) | 2013-06-27 | 2013-06-27 | Polypeptides |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9834589B2 (https=) |
| EP (1) | EP3013854B1 (https=) |
| JP (1) | JP6621741B2 (https=) |
| GB (1) | GB201311475D0 (https=) |
| WO (1) | WO2014207063A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2894511C (en) | 2012-12-11 | 2021-12-07 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| CN114181309B (zh) | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
| CN108513576A (zh) * | 2015-09-14 | 2018-09-07 | 高山免疫科学股份有限公司 | 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗 |
| HRP20240052T1 (hr) | 2016-03-04 | 2024-03-29 | Io Biotech Aps | Kombinirana terapija protiv raka |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| WO2017201210A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN109689096A (zh) | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法 |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| GB201619652D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel polypeptides |
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| US20200009135A1 (en) | 2017-02-01 | 2020-01-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| RU2019138067A (ru) | 2017-05-02 | 2021-06-02 | Эллигейтор Биосайенс Аб | Биспецифическое антитело против ox40 и ctla-4 |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| KR102665499B1 (ko) | 2018-03-09 | 2024-05-14 | 메디비르 아베 | (2,2-비스하이드록시메틸)메틸렌사이클로프로판 뉴클레오티드로의 암 치료 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| MA56462A (fr) | 2019-07-04 | 2022-05-11 | Qilu Regor Therapeutics Inc | Inhibiteurs de hpk1 et leurs utilisations |
| US12565517B2 (en) | 2019-10-08 | 2026-03-03 | Genefrontier Corporation | Cyclic peptide having CTLA-4 inhibitory activity and use thereof |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| GB202103122D0 (en) | 2021-03-05 | 2021-04-21 | Univ London Queen Mary | Treatment |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| EP4472734A1 (en) | 2022-02-03 | 2024-12-11 | C4X Discovery Limited | Heterocyclic derivatives as malt1 inhibitors |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| GB202207050D0 (en) | 2022-05-13 | 2022-06-29 | C4X Discovery Ltd | Therapeutic compounds |
| WO2025104411A1 (en) | 2023-11-15 | 2025-05-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2025104412A1 (en) | 2023-11-15 | 2025-05-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2025137168A2 (en) | 2023-12-19 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Salt and solid forms of a hpk1 inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US6130316A (en) | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
| EP1186300A1 (en) | 1996-03-20 | 2002-03-13 | Bristol-Myers Squibb Company | Pharmaceutical compositions useful for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| EP1341909B2 (en) | 2000-12-12 | 2012-04-11 | Alligator Bioscience AB | A method for in vitro molecular evolution of protein function |
| DK1504098T4 (da) | 2002-05-17 | 2011-05-23 | Alligator Bioscience Ab | Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| GB2432366B (en) | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| GB0920258D0 (en) * | 2009-11-19 | 2010-01-06 | Alligator Bioscience Ab | New medical agents and use thereof |
-
2013
- 2013-06-27 GB GBGB1311475.6A patent/GB201311475D0/en not_active Ceased
-
2014
- 2014-06-25 JP JP2016522479A patent/JP6621741B2/ja not_active Expired - Fee Related
- 2014-06-25 WO PCT/EP2014/063442 patent/WO2014207063A1/en not_active Ceased
- 2014-06-25 US US14/901,202 patent/US9834589B2/en not_active Expired - Fee Related
- 2014-06-25 EP EP14732247.3A patent/EP3013854B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP3013854B1 (en) | 2021-02-24 |
| JP6621741B2 (ja) | 2019-12-18 |
| WO2014207063A1 (en) | 2014-12-31 |
| JP2016526885A (ja) | 2016-09-08 |
| US20160304580A1 (en) | 2016-10-20 |
| US9834589B2 (en) | 2017-12-05 |
| EP3013854A1 (en) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004893B (en) | Materials | |
| GB201311475D0 (en) | Polypeptides | |
| IL240606A0 (en) | New polypeptides | |
| SG11201602889TA (en) | Novel polypeptides | |
| ZA201600729B (en) | Peptides | |
| AU353644S (en) | Stamphousing | |
| ZA201504986B (en) | Peptide | |
| ZA201504987B (en) | Peptide | |
| GB201309421D0 (en) | Polypeptides | |
| GB201315130D0 (en) | Peptides | |
| ZA201506407B (en) | New polypeptides | |
| PL3080276T3 (pl) | Polipeptydy toksyczne dla owadów | |
| GB201318941D0 (en) | Novel polypeptides | |
| AU4899P (en) | Herbie53 Iresine herbstii | |
| AU4977P (en) | Harrosy Gaura lindheimeri | |
| GB201316660D0 (en) | Peptides | |
| GB201300381D0 (en) | Peptides | |
| GB201317353D0 (en) | Ed | |
| GB201303977D0 (en) | Binding polypeptides | |
| AU353331S (en) | Kettlebell | |
| AU353328S (en) | Kettlebell | |
| AU353325S (en) | Kettlebell | |
| AU353329S (en) | Kettlebell | |
| AU2013099V (en) | Little Lorey Chamelaucium floriferum | |
| AP2013000703S (en) | Adwura wura |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |